《大行報告》高盛首予三葉草生物-B(02197.HK)「買入」評級 目標價22.83元
高盛發表研究報告指出,三葉草生物-B(02197.HK)成功開發新冠肺炎候選疫苗SCB-2019(CpG. 1018加鋁佐劑)及其專有的蛋白質三聚體化技術。該疫苗於II/III期臨床試驗中針對Delta變種的效力為78.7%,並已開始向中國藥監局、歐洲藥品管理局及世衛組織提交附條件批准申請,預期將於2021年第四季至2022年上半年獲得批准。
該行相信,三葉草生物截至今日(8日)的市值約為16.7億美元,僅反映公司根據COVAX機制達成的提前採購協議所支持的近期現金流,而公司的疫苗具有良好的安全性,為公司帶來顯著的上行空間。該行預測公司2021至2023年分別錄得淨虧損17億元人民幣、淨利潤62億元人民幣及淨利潤52億元人民幣,基於風險調整後的貼現現金流,料公司估值36億美元,首予其「買入」評級,目標價22.83元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.